Display Settings:

Format

Send to:

Choose Destination
Clin Trials. 2011 Aug;8(4):370-9. doi: 10.1177/1740774511410732.

Incorporating lower grade toxicity information into dose finding designs.

Author information

  • 1Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. iasonosa@mskcc.org

Abstract

BACKGROUND:

Toxicity grades underlie the definition of a dose-limiting toxicity but in the majority of phase I designs, the information contained in the individual grades is not used. Some authors have argued that it may be more appropriate to consider a polytomous rather than dichotomous response.

PURPOSE:

We investigate whether the added information on individual grades can improve the operating characteristics of the continual reassessment method.

METHODS:

We compare the original continual reassessment method design for a binary response with two stage continual reassessment method designs which make different use of lower grade toxicity information via simulations. Specifically, we study a two-stage design that utilizes lower grade toxicities in the first stage only, during the initial non-model-based escalation, and two-stage designs where lower grades are used throughout the trial via explicit models. We postulate a model relating the rates of lower grade toxicities to the rate of dose-limiting toxicity, or assume the relative rates of low-to-high grade toxicities is unknown. The designs were compared in terms of accuracy, patient allocation, and precision.

RESULTS:

Significant gains can be achieved when using grades in the first stage of a two-stage design. Otherwise, only modest improvements are seen when the information on grades is exploited via the use of explicit models, where the parameters are known precisely. Continual reassessment method with some use of grade information, increases the number of patients treated at the maximum tolerated dose by approximately 5%. The additional information from lower grades can lead to a small increase in the precision of our estimate of the maximum tolerated dose.

LIMITATIONS:

Our comparisons are not exhaustive and it would be worth studying other models and situations.

CONCLUSIONS:

Although the gains in performance were not as great as we had hoped, we observed no cases where the performance of continual reassessment method was poorer. Our recommendation is that investigators might consider using graded toxicities at the design stage.

PMID:
21835856
[PubMed - indexed for MEDLINE]
PMCID:
PMC3293181
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk